Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

Tetanus Clinical Trial

Official title:

Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01323959
• Other study ID #: 113060
• Status: Completed
• Phase: Phase 4
• Start date: April 1, 2011
• Est. completion date: March 1, 2012

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.

Description:

This protocol posting has been updated following protocol amendment 1, dated 03 June 2011. The impacted section is: Eligibility Criteria (Exclusion criteria).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 212
• Est. completion date: March 1, 2012
• Est. primary completion date: March 1, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes can and will comply with the requirements of the protocol.

• Male or female subjects who have received vaccine in study NCT01277705.

• Written informed consent obtained from the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• Female subjects of non-childbearing potential may be enrolled in the study.

• Female subjects of childbearing potential may be enrolled in the study and receive the booster vaccine, if the subject:

• practices/has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test on the day of vaccination, and

• agrees to continue adequate contraception during the entire booster epoch.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of the study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.

• Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.

• Previous booster vaccination against diphtheria, tetanus, pertussis or poliovirus since the dose received in study NCT01277705. In Germany, previous dose of a monovalent vaccine against pertussis is allowed for subjects in the Group C.

• History of diphtheria, tetanus, pertussis or poliomyelitis diseases following the receipt of booster dose in study NCT01277705.

• Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination.

• Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.

• Occurrence of any of the following adverse event after a previous administration of a DTP vaccine:

• Hypersensitivity reaction to any component of the vaccine,

• encephalopathy of unknown aetiology occurring within seven days following previous vaccination with pertussis-containing vaccine,

• fever = 40°C within 48 hours of vaccination not due to another identifiable cause,

• collapse or shock-like state within 48 hours of vaccination,

• convulsions with or without fever, occurring within 3 days of vaccination.

• Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.

• Acute disease and/or fever at the time of enrolment.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Acellular Pertussis
• Diphtheria
• Poliomyelitis
• Tetanus

Intervention

Biological:
• BoostrixTM Polio
Single dose, intramuscular administration.

Locations

Country	Name	City	State
France	GSK Investigational Site	Derval
France	GSK Investigational Site	La Chapelle Basse Mer
France	GSK Investigational Site	La Riche
France	GSK Investigational Site	Nantes
France	GSK Investigational Site	Nantes cedex 2
France	GSK Investigational Site	Tours
France	GSK Investigational Site	Tours
Germany	GSK Investigational Site	Deggendorf	Bayern
Germany	GSK Investigational Site	Hoehenkirchen-Siegertsbrunn	Bayern
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Regensburg	Bayern
Germany	GSK Investigational Site	Selbitz	Bayern
Germany	GSK Investigational Site	Vilshofen	Bayern
Germany	GSK Investigational Site	Weilheim	Bayern
Germany	GSK Investigational Site	Wuerzburg	Bayern

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens	A seroprotected subject is defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (=) 0.1 international units per millilitre (IU/mL).	At Month 1
Primary	Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3	A seroprotected subject is defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 antibody concentration greater than or equal to (=) 8 Effective Dose 50 (ED50)	At Month 1
Primary	Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens	A seroprotected subject is defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (=) 0.1 international units per millilitre (IU/mL)	At Day 0
Primary	Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3	A seroprotected subject is defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 antibody concentration greater than or equal to (=) 8 Effective Dose 50 (ED50)	At Day 0
Primary	Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN) Antibodies	Cut-off values assessed were greater than or equal to = 5 Enzyme Linked Immunosorbent Assay (ELISA) units per millilitre (EL.U/ml)	At Day 0
Primary	Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per millilitre (IU/mL)	At Day 0
Primary	Anti-polio 1, Anti-polio 2 and Anti-polio 3 Antibody Titers	Titers are presented as geometric mean titers (GMTs).	At Day 0
Primary	Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN) Antibodies Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in expressed in ELISA units per millilitre (EL.U/mL)	At Day 0
Secondary	Number of Subjects With Booster Response to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)	Booster response was defined as: for initially seronegative subjects: antibody concentration = 20 EL.U/mL at post booster vaccination; for initially seropositive subjects with pre-vaccination antibody concentration < 20 EL.U/mL: antibody concentration at post booster = 4 fold the pre-vaccination antibody concentration; and for initially seropositive subjects with pre-vaccination antibody concentration = 20 EL.U/mL: antibody concentration at post booster = 2 fold the pre-vaccination antibody concentration.	At Month 1
Secondary	Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN) Antibodies Above the Cut-off	Cut-off values assessed were greater than or equal to = 5 Enzyme Linked Immunosorbent Assay (ELISA) units per millilitre (EL.U/ml)	At Month 1
Secondary	Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per millilitre (IU/mL)	At Month 1
Secondary	Anti-polio 1, Anti-polio 2 and Anti-polio 3 Antibody Titers	Titers are presented as geometric mean titers (GMTs).	At Month 1
Secondary	Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN) Antibodies Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in expressed in ELISA units per millilitre (EL.U/mL)	At Month 1
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.	During the 4-day (Day 0-Day 3) follow-up period after vaccination
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.	Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (=) 37.5 degrees Celsius (°C)], headache and gastrointestinal symptoms. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 4-day (Day 0-Day 3) follow-up period after vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs).	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 31-day (Day 0-Day 30) follow-up period after vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs).	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Month 0 - Month 1

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.